Adaptimmune Therapeutics Valuation
| ADAP Stock | USD 0.25 0.03 10.71% |
Adaptimmune Therapeutics seems to be undervalued based on Macroaxis valuation methodology. Our model approximates the value of Adaptimmune Therapeutics from analyzing the firm fundamentals such as profit margin of (0.25) %, and Return On Equity of -0.53 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Adaptimmune Therapeutics' valuation include:
Price Book 0.8855 | Enterprise Value | Enterprise Value Ebitda (1.71) | Price Sales 0.4046 | Enterprise Value Revenue 0.6423 |
Undervalued
Today
Please note that Adaptimmune Therapeutics' price fluctuation is abnormally volatile at this time. Calculation of the real value of Adaptimmune Therapeutics is based on 3 months time horizon. Increasing Adaptimmune Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Adaptimmune Therapeutics' intrinsic value may or may not be the same as its current market price of 0.25, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.25 | Real 0.75 | Target 2.27 | Hype 0.25 | Naive 0.21 |
The intrinsic value of Adaptimmune Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Adaptimmune Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Adaptimmune Therapeutics Plc helps investors to forecast how Adaptimmune stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Adaptimmune Therapeutics more accurately as focusing exclusively on Adaptimmune Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Adaptimmune Therapeutics' intrinsic value based on its ongoing forecasts of Adaptimmune Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Adaptimmune Therapeutics' closest peers.
Adaptimmune Therapeutics Cash |
|
Adaptimmune Valuation Trend
Adaptimmune Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Adaptimmune Therapeutics' financial worth over time. Using both Adaptimmune Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Adaptimmune Therapeutics Total Value Analysis
Adaptimmune Therapeutics Plc is presently forecasted to have valuation of (40.77 M) with market capitalization of 70.83 M, debt of 234.11 M, and cash on hands of 199.67 M. The negative valuation of Adaptimmune Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Adaptimmune Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(40.77 M) | 70.83 M | 234.11 M | 199.67 M |
Adaptimmune Therapeutics Investor Information
About 50.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.89. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adaptimmune Therapeutics has Price/Earnings To Growth (PEG) ratio of 0.11. The entity recorded a loss per share of 0.17. The firm last dividend was issued on the 30th of March 2018. Based on the key indicators related to Adaptimmune Therapeutics' liquidity, profitability, solvency, and operating efficiency, Adaptimmune Therapeutics Plc is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Adaptimmune Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Adaptimmune Therapeutics has an asset utilization ratio of 72.38 percent. This connotes that the Company is making $0.72 for each dollar of assets. An increasing asset utilization means that Adaptimmune Therapeutics Plc is more efficient with each dollar of assets it utilizes for everyday operations.Adaptimmune Therapeutics Ownership Allocation
Adaptimmune Therapeutics holds a total of 255.88 Million outstanding shares. 30% of Adaptimmune Therapeutics Plc outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Adaptimmune Therapeutics Profitability Analysis
The company reported the previous year's revenue of 178.03 M. Net Loss for the year was (70.81 M) with profit before overhead, payroll, taxes, and interest of 31.87 M.About Adaptimmune Therapeutics Valuation
The stock valuation mechanism determines Adaptimmune Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Adaptimmune Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Adaptimmune Therapeutics. We calculate exposure to Adaptimmune Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Adaptimmune Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 178 M | 186.9 M | |
| Pretax Profit Margin | (0.38) | (0.40) | |
| Operating Profit Margin | (0.39) | (0.41) | |
| Net Loss | (0.40) | (0.42) | |
| Gross Profit Margin | 1.00 | 1.05 |
Adaptimmune Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Adaptimmune Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.5 B |
Adaptimmune Therapeutics Current Valuation Indicators
Adaptimmune Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Adaptimmune Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Adaptimmune Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Adaptimmune Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Adaptimmune Therapeutics' worth.Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.